Erectile Dysfunction Drugs Market - Forecast(2024 - 2030)

Report Code: HCR 0908 Report Format: PDF + Excel

Erectile Dysfunction Drugs Market Overview 

Erectile Dysfunction Drugs Market size is valued at $2.5Bn by 2023, and is anticipated to reach at $4.91 Bn by 2030 by growing at a CAGR of 8.8% during the forecast period 2024-2030. The Erectile Dysfunction Drugs Market growth rate is attributed to a high incidence rate of chronic diseases including hypertension, neurogenic and psychological disorders, and diabetes. Apart from these, rising aged population, alcoholism, sedentary lifestyles, and smoking greatly increases the risk of erectile dysfunction, growing adoption of these poor lifestyle choices leads to the overall growth of the market for erectile dysfunction drugs. From wide range of interventions that include exercise, change in life style like smoking cessation and reduction in alcohol intake, pharmacotherapy, erection devices, penile implants, and drug injections into penis to the growing patient willingness to seek medical assistance for disease management is anticipated to propel the Erectile Dysfunction Drugs Market during the forecast period 2024-2030. One notable trend in the erectile dysfunction (ED) drugs market is the increasing preference for non-pharmacological treatments. While pharmaceutical interventions such as PDE5 inhibitors have been the cornerstone of ED treatment, there is a growing recognition of the importance of lifestyle changes, psychological interventions, and non-invasive therapies. This trend is driven by factors such as concerns over medication side effects, desire for long-term solutions, and the growing understanding of the multifactorial nature of ED. Consequently, there is a rising demand for alternative treatments such as vacuum erection devices, penile implants, shockwave therapy, and psychotherapy. Manufacturers and healthcare providers are responding to this trend by expanding their product portfolios to include a broader range of non-pharmacological options, offering patients more personalized and holistic approaches to managing erectile dysfunction. A notable trend in the erectile dysfunction (ED) drugs market is the increasing emphasis on personalized medicine and targeted therapies. Traditional ED treatments, such as phosphodiesterase type 5 (PDE5) inhibitors, may not be equally effective for all patients due to individual variations in physiology, underlying health conditions, and medication response. As a result, there is a growing interest in developing tailored treatment approaches that address the specific needs and preferences of each patient. This trend involves leveraging advancements in precision medicine, pharmacogenomics, and biomarker identification to identify optimal treatment strategies based on genetic profiles, biomarkers, and other patient-specific factors. Additionally, research into novel therapeutic targets and mechanisms of action is leading to the development of targeted therapies that address the underlying causes of ED, such as vascular dysfunction, hormonal imbalances, or neurological disorders. By focusing on personalized medicine and targeted therapies, the ED drugs market aims to improve treatment outcomes, minimize side effects, and enhance patient satisfaction.

Market Snapshot: 


Report Coverage

The report: “Erectile Dysfunction Drugs Market Forecast (2024-2030)”, by Industry ARC, covers an in-depth analysis of the following segments of the Erectile Dysfunction Drugs Market:


By Drug Type: Sildenafil Citrate (Viagra), Vardenafil (Levitra/Staxyn), Tadalafil (Cialis), Udenafil (Zydena), Lodenafil Carbonate (Helleva), Stendra/ Spedra (Avanafil), Mirodenafil (Mvix), and Others.

By Mode of Administration: Oral Medications, Topical Medications, Injections and Others.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Sales and Others.

By Geography: North America, Europe, Asia-Pacific and RoW.


Key Takeaways

  • North America dominated the Erectile Dysfunction Drugs Market with a share of 39% in the year 2023.
  • The factors such as increasing disease awareness and the increasing presence of favorable guidelines for disease management are amongst the major factor projected to impel growth of Erectile Dysfunction Drugs Market.
  • Patient awareness and education, a growing number of campaigns by government and non-government organizations worldwide to make patients aware of the disease are the key factors owing to the growth in the segment during forecast period 2020-2025.

  For More Details on This Report - Request for Sample

Drug Type - Segment Analysis

Sildenafil Citrate (Viagra) segment held the largest share in the market as it is one of the most widely distributed products worldwide over other drugs and is poised to grow at a CAGR of 5.31% over the forecast period 2024-2030. Also, it is distinguished from other PDE 5 inhibitors for its longer duration of action and lesser incidences of side effects such as vision disturbances and muscle pain. Furthermore, the novel molecule combinations and drug delivery techniques such as the use of creams and pellets that shows better efficacy and performance which is to propel the ED drug segmental market in the forecast period of 2024-2030.

Distribution Channel- Segment Analysis

On the basis of distribution channel, retail pharmacies segment held the major share of the market in terms of revenue and set to witness lucrative growth over the forecast period 2024-2030. The reason may be attributed to the easy availability of the drug and rising cases of ED in the market. The presence of retail pharmacies is a blessing in disguise for several patients who are conscious about visiting a retail pharmacy store to purchase drugs for erectile dysfunction and other sexual wellness products is anticipated to further expand the consumption rate over the projection period of 2024-2030. 

By Geography - Segment Analysis

North America dominated the Erectile Dysfunction Drugs Market with a share of 39% in 2019. The application of Erectile Dysfunction Drugs has grown rapidly over the last few years in North America owing to the rising geriatric population, increase in cases of ED and the presence of better healthcare infrastructure. According to an article published by Preferredmensmedical, In the US, over 30 million men are afflicted by erectile dysfunction. Moreover, In a US survey on men aged 40 and older, the prevalence of ED in men was found to be 21.9% white, 24.4% black, and 19.9% Hispanic men. The rise in geriatric population is set to increase the number of patients suffering from ED, as it is very common in men above age 40. The availability of various ED drugs through over the counter (OTC) and online channels are to cater the Erectile Dysfunction Drugs Market in the forecast period of 2024-2030.


Drivers – Erectile Dysfunction Drugs Market

Increase adoption of poor lifestyle choices

With the rise in the adoption of poor lifestyle which leads to the high growth of obesity, diabetes and cardiovascular disorders; which in long term leads to the problems like ED with age. Moreover, with the increase in the geriatric population there has an increase in the number of ED cases which is considered as a Erectile Dysfunction Drugs key driver of the market during the forecast period 2024-2030. 


Challenges – Erectile Dysfunction Drugs Market

Increase availability of counterfeit ED drugs

The major challenge for the market is the increasing manufacturing of generic erectile dysfunction drugs as well as the increasing availability of counterfeit erectile dysfunction drugs. Owing to the lucrative marketing of counterfeit erectile dysfunction drugs at much lower prices than either patented or generic drugs, consumers are often preferring lower priced generic variants of erectile dysfunction drugs than more expensive blockbuster varieties. Apart from this, owing to the expiry of patent for blockbuster drugs, many generic variants are coming into the market, usually at low prices.

Erectile Dysfunction Drugs Industry Outlook

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Erectile Dysfunction Drugs Market. In 2019, Erectile Dysfunction Drugs Market share is fragmented by the top ten players present in the market. Erectile Dysfunction Drugs Market top 10 companies are Pfizer, Bayer AG, Eli Lilly & Co., GlaxoSmithKline Plc., Coloplast A/S, S.K. Chemicals Co. Ltd., Vivus Inc., Apricus Biosciences, Futura Medical, Rigicon and others.

Acquisitions/Product Launches

  • In 2023, Rigicon, Inc. launched the HL-LEVINE Combo Prosthesis Tool, which is a combination of the HL dilator tool and the traditional Furlow instrument, which are both used for penile implant surgery.
  • In 2022, Advanced MedTech Holdings acquired Shenzhen Huikang Medical Apparatus Co., Ltd. This acquisition expanded Advanced MedTech's urological market access in China via a comprehensive nationwide sales and service network and an established local R&D, manufacturing, and supply chain ecosystem.
1. Erectile Dysfunction Drugs Market Overview
    1.1 Definitions and Scope
2. Erectile Dysfunction Drugs Market - Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Drug Type
    2.3 Key trends by Mode of Application
    2.4 Key trends by Geography
3. Erectile Dysfunction Drugs Market – Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Erectile Dysfunction Drugs Market - Startup Companies Scenario 
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Erectile Dysfunction Drugs Market – Industry Market Entry Scenario Premium 
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Erectile Dysfunction Drugs Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes 
7. Erectile Dysfunction Drugs Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Erectile Dysfunction Drugs Market – By Drug Type (Market Size –$Million/$Billion)
    8.1 Viagra (Sildenafil Citrate)
    8.2 Levitra/Staxyn (Vardenafil)
    8.3 Cialis (Tadalafil)
    8.4 Zydena (Udenafil)
    8.5 Helleva (Lodenafil Carbonate)
    8.6 Avanafil (Stendra/ Spedra)
    8.7 Mvix (Mirodenafil)
    8.8 Others
9. Erectile Dysfunction Drugs Market – By Mode of Administration (Market Size –$Million/$Billion)
    9.1 Oral Medications
    9.2 Topical Medications
    9.3 Injections
    9.4 Others
10. Erectile Dysfunction Drugs Market – By Distribution Channel (Market Size –$Million/$Billion)
    10.1 Hospital Pharmacies
    10.2 Retail Pharmacies
    10.3 Online Sales
    10.4 Others
11. Erectile Dysfunction Drugs Market - By Geography (Market Size –$Million/$Billion)
    11.1 North America
        11.1.1 U.S.
        11.1.2 Canada
        11.1.3 Mexico
    11.2 Europe
        11.2.1 U.K.
        11.2.2 Germany
        11.2.3 France
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Rest of Europe
    11.3 Asia-Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5 Australia & New Zealand
        11.3.6 Rest of Asia-Pacific
    11.4 South America
        11.4.1 Brazil
        11.4.2 Argentina
        11.4.3 Chile 
        11.4.4 Colombia
        11.4.5 Others
    11.5 Rest of the World
        11.5.1 Middle East
        11.5.2 Africa
12. Erectile Dysfunction Drugs Market - Entropy
13. Erectile Dysfunction Drugs Market – Industry/Segment Competition Landscape 
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key companies
        13.1.3 Market Share by Countries – Key Companies
        13.1.4 Best Practices for Companies
14. Erectile Dysfunction Drugs Market – Key Company List by Country Premium
15. Erectile Dysfunction Drugs Market Company Analysis
    15.1 Pfizer Inc.
    15.2 Bayer AG
    15.3 Eli Lilly and Company
    15.4 GlaxoSmithKline Plc.
    15.5 Coloplast A/S
    15.6 SK chemicals
    15.7 Vivus Inc.
    15.8 Apricus Biosciences
    15.9 Futura Medical
    15.10 Rigicon
"*Financials for private companies would be provided on a best effort basis”.
Connect with our experts to get customized reports that best suit your requirements. Our reports include global-level data, niche markets and competitive landscape